Articles by Jill Wechsler - Pharmaceutical Executive


Articles by Jill Wechsler

Obamacare, Innovation and Pricing

Dec 1, 2012

Tax and budget decisions will shape the healthcare market and drug research and regulation.

Budgets, Biosimilars, and Bad Ads

Nov 1, 2012

While the nation was embroiled in the presidential elections, a number of important legal and regulatory issues absorbed pharmaceutical executives, writes Jill Wechsler.

Latest Changes and Challenges at FDA

Oct 1, 2012

New user fee programs precipitate major changes at an agency under constant and intense scrutiny, writes Jill Wechsler.

Costs, Coverage, and Court Decisions

Sep 1, 2012

Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare.

Fleshing Out FDASIA

Aug 1, 2012

Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation.

Who Will Pay for New Drugs?

Jul 1, 2012

Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies. Jill Wechsler reports.

Innovation and Collaboration

Jun 1, 2012

A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.

Comparative Effectiveness Research: Challenges for Pharma

May 9, 2012

Switching Rx drugs to OTC and adding comparative data could broaden access to treatment, writes Jill Wechsler.

Shortages and Sunshine

Apr 1, 2012

Disclosure rules the day, as industry confronts demands to report supply problems, results of clinical trials, and payment to doctors.


Click here